Scientific activity and scientific production
"Cima's scientific activity has generated publications in journals of high scientific impact, patented biomedical inventions and coordination in international projects."
ANTONIO PINEDA
SCIENTIFIC DIRECTOR. CIMA UNIVERSIDAD DE NAVARRA
2024-2025 in data
254
scientific publications in total
208
In the first quartile
132
With authorship
111
In the first quartile with authorship
Strategic alliances
Outstanding scientific publications
Year 2022
|
|
|
Alonso MM et al. New England Journal of Medicine. |
| Pastor F. Molecular Cancer. División de Innovación Tecnológica Primer decil. Top 3 |
|
|
|
Pastor F. Molecular Cancer. |
|
|
| Berraondo P et al. Annals of Oncology. División de Cáncer Primer decil. |
|
|
| Calvo A et al. Nature Medicine División de Cáncer Primer decil. Top 3 |
|
|
| San Miguel J et al. Journal of Clinical Oncology. División de Cáncer Primer decil |
|
|
| Diez J et al. European Heart Journal. División Cardiovascular Primer decil. Top 3 |
| Paiva B et al. Journal of ClinicalOncology. División de Cáncer Primer decil. |
| Lecanda F et al. Cancer Discovery. Colaboración Dr. Vicent División de Cáncer Primer decil |
|
|
| San Miguel J et al. The Lancet Haematology. División de Cáncer Primer decil. Top 3 |
|
|
| Melero I et al. Cancer Discovery División de Cáncer Primer decil. |
| Odero MD et al. Blood. División de Cáncer Primer decil. Top 3 |
| Prósper F et al. Cell Metabolism. División de Cáncer Primer decil. Top 3 |
| Fontanellas A et al. Science Traslational Medicine. División de Cáncer Primer decil. Top 3 |
|
|
| Dubrot J et al. Nature Immunology División de Cáncer Primer decil. |
|
|
| Ortiz de Solórzano C et al. Medical Image Analysis División de Innovación Tecnológica Primer decil. Top 3 |
Grants for SINAI members to carry out collaborative R&D projects in 2024
Awarded to the FOUNDATION FOR APPLIED MEDICAL RESEARCH
Grant No.: 0011-1383-2024-000011
Total grant awarded: €1,329,106.42
Scientific activity of the
Cima Universidad de Navarra
Latest scientific publications
- Radiotherapy protocols for mouse cancer model Mar 19, 2026 | Magazine: Cancer Cell
- Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab Mar 16, 2026 | Magazine: Clinical Cancer Research
- Immune biomarkers of increased infection risk in multiple myeloma Jan 29, 2026 | Magazine: Blood
- Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA Jan 1, 2026, | Magazine: Theranostics